Cargando…
Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
Treatment-resistant schizophrenia (TRS) poses a significant therapeutic challenge in psychiatric practice. Clozapine is recognized as a treatment of choice in TRS but is not always effective in alleviating patients’ symptoms. Additionally, clozapine therapy is associated with multiple side effects a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889903/ https://www.ncbi.nlm.nih.gov/pubmed/36700327 http://dx.doi.org/10.9758/cpn.2023.21.1.202 |
_version_ | 1784880834130477056 |
---|---|
author | Montgomery, Adam Rogowska, Marianna Dratcu, Luiz |
author_facet | Montgomery, Adam Rogowska, Marianna Dratcu, Luiz |
author_sort | Montgomery, Adam |
collection | PubMed |
description | Treatment-resistant schizophrenia (TRS) poses a significant therapeutic challenge in psychiatric practice. Clozapine is recognized as a treatment of choice in TRS but is not always effective in alleviating patients’ symptoms. Additionally, clozapine therapy is associated with multiple side effects and monitoring requirements that often limit its use and negatively affect patients’ compliance with the treatment. Although clozapine augmentation options are available, there is currently no alternative monotherapy proven to be effective in TRS. We present a case of a young man with TRS who failed to respond to appropriate trials of risperidone, aripiprazole and also clozapine, and who experienced impairing adverse effects of clozapine that made further clozapine treatment not only futile but also detrimental to his health. He was successfully treated with cariprazine monotherapy, which culminated in the remission of his both positive and negative symptoms of psychosis as well as in the marked improvement in social functioning. Cariprazine, a newer atypical antipsychotic endowed with a D3-preferring mode of action, may offer a better tolerated and more acceptable treatment option for patients with difficult-to-treat psychotic symptoms. |
format | Online Article Text |
id | pubmed-9889903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean College of Neuropsychopharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-98899032023-02-28 Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? Montgomery, Adam Rogowska, Marianna Dratcu, Luiz Clin Psychopharmacol Neurosci Case Report Treatment-resistant schizophrenia (TRS) poses a significant therapeutic challenge in psychiatric practice. Clozapine is recognized as a treatment of choice in TRS but is not always effective in alleviating patients’ symptoms. Additionally, clozapine therapy is associated with multiple side effects and monitoring requirements that often limit its use and negatively affect patients’ compliance with the treatment. Although clozapine augmentation options are available, there is currently no alternative monotherapy proven to be effective in TRS. We present a case of a young man with TRS who failed to respond to appropriate trials of risperidone, aripiprazole and also clozapine, and who experienced impairing adverse effects of clozapine that made further clozapine treatment not only futile but also detrimental to his health. He was successfully treated with cariprazine monotherapy, which culminated in the remission of his both positive and negative symptoms of psychosis as well as in the marked improvement in social functioning. Cariprazine, a newer atypical antipsychotic endowed with a D3-preferring mode of action, may offer a better tolerated and more acceptable treatment option for patients with difficult-to-treat psychotic symptoms. Korean College of Neuropsychopharmacology 2023-02-28 2023-02-28 /pmc/articles/PMC9889903/ /pubmed/36700327 http://dx.doi.org/10.9758/cpn.2023.21.1.202 Text en Copyright© 2023, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Montgomery, Adam Rogowska, Marianna Dratcu, Luiz Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? |
title | Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? |
title_full | Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? |
title_fullStr | Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? |
title_full_unstemmed | Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? |
title_short | Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? |
title_sort | cariprazine — an alternative treatment for clozapine-resistant schizophrenia? |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889903/ https://www.ncbi.nlm.nih.gov/pubmed/36700327 http://dx.doi.org/10.9758/cpn.2023.21.1.202 |
work_keys_str_mv | AT montgomeryadam cariprazineanalternativetreatmentforclozapineresistantschizophrenia AT rogowskamarianna cariprazineanalternativetreatmentforclozapineresistantschizophrenia AT dratculuiz cariprazineanalternativetreatmentforclozapineresistantschizophrenia |